| Trial/reference | Randomly assigned patients | Disease characteristics | Active treatment groups (n) | Control group (n) | Duration of trial |
| TNR 00102Unpublished | 158 (153)* | Active RA with inadequate response to MTX | Etanercept 10 mg biw (52) | Placebo (50) | 12 Weeks |
| Etanercept 25 mg biw (52) | |||||
| 160004Moreland et al, 199720 | 180 (180) * | Active RA with inadequate response to ⩾1 DMARD | Etanercept 0.25 mg/m2 biw (46) | Placebo (44) | 12 Weeks |
| Etanercept 2.0 mg/m2 biw (46) | |||||
| Etanercept 16.0 mg/m2 biw (44) | |||||
| 160009Moreland et al, 199921 | 246 (234) * | Active RA with inadequate response to ⩾1 DMARD | Etanercept 10 mg biw (76) | Placebo (80) | 26 Weeks |
| Etanercept 25 mg biw (78) | With extension up to 52 weeks | ||||
| 160012Bathon et al, 20006 | 654 (632)* | Active early RA <3 years (no previous MTX) | Etanercept 10 mg biw (208) | Placebo + MTX (217) | 104 Weeks |
| Etanercept 25 mg biw (207) | |||||
| Genovese et al, 200218 | |||||
| 160014 | 89 (89)* | Active RA with inadequate response to MTX | Etanercept 25 mg biw + MTX (59) | Placebo + MTX (30) | 24 Weeks |
| Weinblatt et al, 199923 | |||||
| 160029 | 564 (534)* | Active RA and at least one comorbidity that increases the likelihood of infection | Etanercept 25 mg biw (266) | Placebo (269) | 16 Weeks |
| Baumgartner et al, 200424 (abstract) | |||||
| 0881300Ericson and Wadjula, 199926 (abstract) | 559 (558)* | Active RA with inadequate response to ⩾1 DMARD | Etanercept 10 mg qw (122) | Placebo (105) | 12 Weeks |
| Etanercept 25 mg qw (111) | |||||
| Etanercept 10 mg biw (110) | |||||
| Etanercept 25 mg biw (111) | |||||
| 0881308Klareskog et al, 200419 | 686 (682)* | Active RA with inadequate response to DMARD other than MTX | Etanercept 25 mg biw (223) | MTX + placebo (228) | Approx 180 weeks |
| Etanercept 25 mg biw + MTX (231) | |||||
| van der Heijde et al, 200622 | |||||
| van der Heijde et al, 200628 (abstract) | |||||
| Mola et al, 200627 (abstract) | |||||
| 0881309Combe et al, 200617 | 260 (254)* | Active RA with inadequate response to sulfasalazine | Etanercept 25 mg biw + sufasalazine (101) | Sulfasalazine + placebo (50) | 104 Weeks |
| Etanercept 25 mg biw + placebo (103) | |||||
| Combe et al, 200525 (abstract) |
*Values in parentheses refer to the number of randomly assigned patients who received at least one allocated treatment dose. biw, twice weekly; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; qw, every week; RA, rheumatoid arthritis.